Aquestive Therapeutics (AQST) Q1 2025: $8.7M Revenue Drop Highlights Anafilm Launch Bet
Aquestive’s Q1 marks a decisive pivot: operational focus and cash are being funneled into the anticipated 2026 launch of Anafilm, its oral epinephrine film. Despite a steep revenue decline from legacy products, leadership is betting on first-mover advantage and commercial readiness to drive a turnaround. Investors should watch for FDA review milestones and balance sheet moves as the company enters a make-or-break commercialization phase.
Summary
- Commercial Launch Preparation Intensifies: Aquestive is reallocating resources to maximize Anafilm’s early 2026 launch window.
- Legacy Revenue Erosion Accelerates: Ongoing declines in Suboxone and Libervant force sharper focus on pipeline execution.
- Capital and Regulatory Watch: Near-term value hinges on FDA progress and ex-US partnership or financing moves.
Performance Analysis
Q1 2025 saw total revenue fall to $8.7 million, down 28% year-over-year, driven by ongoing declines in Suboxone, a legacy opioid dependence film, and the removal of Libervant revenue following regulatory setbacks. Manufacturer and supply revenue dropped to $7.2 million, with only partial offset from newer collaborations such as Andif, Simpazan, and Emilis. License and royalty revenue also contracted, reflecting terminated agreements and lower Astarys royalties. Proprietary product revenue grew but remains too small to offset core declines. R&D expense fell as clinical investment in AQST-108 was paused, freeing up capital for Anafilm pre-launch activity, while SG&A rose sharply to $19.1 million, reflecting regulatory fees, legal costs, and commercial buildout for Anafilm. The result was a widened net loss of $22.9 million and a non-GAAP adjusted EBITDA loss of $17.6 million.
Cash and equivalents stood at $68.7 million, with management emphasizing “runway through this year and the initial stages” of launch, but underscoring the need for additional funding or partnership to support a full-scale commercial rollout. Revised 2025 guidance now excludes Libervant revenue entirely, projecting $44 million to $50 million in revenue and a $47 million to $51 million adjusted EBITDA loss, both heavily influenced by Anafilm launch spending.
- Legacy Revenue Attrition: Suboxone and Libervant declines outpaced gains from newer products, underscoring urgency for pipeline success.
- Commercial Spend Surge: SG&A growth signals a decisive shift toward Anafilm launch execution, with regulatory and marketing costs front-loaded.
- Cash Burn and Funding Levers: Paused AQST-108 and Libervant efforts free up capital, but non-dilutive financing or ex-US deals remain essential to sustain launch momentum.
Operational results confirm Aquestive’s transformation into a single-asset, launch-driven story, where near-term value will be dictated by regulatory milestones and execution against a tight commercial timeline.
Executive Commentary
"We are now over a month into our FDA review for anafilm epinephrine sublingual film, which, if approved by the FDA, will be the first and only oral medication indicated for the treatment of severe allergic reactions, including anaphylaxis... We have officially entered the commercial prelaunch phase for Anifilm."
Dan Barber, Chief Executive Officer
"We have said we are not hiring one sales rep until we have approval. We will do all the preparatory work, we'll do all the pre-commercial work this year, but we will not spend money on sales reps until we have approval and then we will ramp up to be prepared to sell as soon as possible. Our cash provides us runway through this year and the initial stages of that launch next year. But we have a number of levers to pull on how rapidly we spend our cash."
Ernie Toth, Chief Financial Officer
Strategic Positioning
1. Anafilm as Core Value Driver
Management is betting the company’s future on Anafilm, an oral epinephrine film developed on its PharmFilm platform, positioned as a more convenient, device-free alternative for anaphylaxis rescue. The launch is expected in Q1 2026, contingent on FDA approval, and is supported by a commercial team with EpiPen experience and established payer contracts from prior products.
2. Market Expansion and Differentiation
Pre-launch activities emphasize awareness-building among physicians, payers, and advocacy groups, with the goal of driving preference for Anafilm’s portability and ease of use. Extensive conference presence and publication volume are being used to outpace recent nasal spray competitors, while direct-to-consumer (DTC) efforts are planned to amplify demand as coverage builds.
3. Capital Efficiency and Resource Allocation
Cash conservation is central: R&D on AQST-108 and all Libervant support is paused, freeing millions for Anafilm. Management is exploring ex-US partnerships (targeting Canada, UK, Germany) and potential debt refinancing to extend runway through launch and into 2027.
4. Commercial Infrastructure and Access
Sales force build will be tightly sequenced with approval, starting with about 50 representatives targeting top allergists and pediatricians. Existing distribution and payer contracts are expected to accelerate initial coverage, with a goal of reaching 80% payer access within six months post-launch, just ahead of the critical back-to-school season.
5. Regulatory and Operational Readiness
FDA review is on schedule, with the 74-day acceptance letter expected in June and a possible advisory committee (adcom) later in the year. The regulatory team is also preparing submissions for key international markets, aiming to maximize Anafilm’s global value proposition.
Key Considerations
This quarter marks a strategic inflection point, as Aquestive pivots from a legacy manufacturing-reliant model to a high-risk, high-reward launch platform for Anafilm. Execution, capital discipline, and regulatory progress are now the primary value levers.
Key Considerations:
- First-Mover Advantage in Oral Epinephrine: Anafilm’s unique, device-free format could reshape patient and prescriber preferences if awareness and access strategies succeed.
- Commercial Team Track Record: Leadership’s EpiPen experience and existing payer/distribution contracts may shorten the path to market penetration.
- Cash Runway and Funding Optionality: Paused non-core R&D and ex-US partnership efforts are designed to preserve capital, but dilution or debt remain possible if launch costs exceed expectations.
- Regulatory Timing and Risks: FDA process remains on track, but adcom outcomes and reviewer changes could introduce delays or uncertainty.
- Market Expansion Potential: Competitor DTC campaigns and rising disease awareness are expanding the overall epinephrine market, potentially lifting all players but also intensifying competition.
Risks
Material risks center on regulatory approval, including the potential for FDA delays or unexpected adcom outcomes. Commercial execution risk is elevated, as initial uptake depends on rapid payer coverage and effective awareness-building. Cash burn remains a concern, with additional capital likely needed if Anafilm’s launch is delayed or slower than expected. Macro volatility, while currently manageable, could impact supply chain or financing options.
Forward Outlook
For Q2 2025, Aquestive expects:
- Minimal Libervant revenue, with guidance now fully excluding this product.
- Continued ramp in Anafilm pre-commercial spend, with no sales force hires until FDA approval.
For full-year 2025, management guides to:
- Total revenue of $44 million to $50 million, reflecting legacy product declines and no Libervant contribution.
- Non-GAAP adjusted EBITDA loss of $47 million to $51 million, driven by Anafilm launch investment.
Management highlighted several factors that will shape the outlook:
- FDA review milestones, including the 74-day acceptance letter and possible adcom, are critical inflection points.
- Balance sheet actions (ex-US licensing, debt refinancing) are under active consideration to fund launch through 2027.
Takeaways
Aquestive is now a launch-centric, single-asset story, with Anafilm’s regulatory and commercial success central to any future upside.
- Legacy Erosion Accelerates Urgency: Declines in Suboxone and the loss of Libervant revenue underscore the need for Anafilm’s timely and effective launch.
- Execution Will Define Value: Commercial readiness, payer access, and rapid awareness-building are essential to capturing first-mover advantage in the oral epinephrine market.
- Investors Should Track FDA and Funding Milestones: The next six months will be pivotal as the company pursues regulatory clarity and non-dilutive funding to support launch scale.
Conclusion
Aquestive’s Q1 results crystallize a high-stakes transition: operational and financial resources are being concentrated on Anafilm’s 2026 launch, with legacy product declines amplifying both risk and opportunity. Regulatory milestones, commercial execution, and capital discipline will determine whether the company’s bet on oral epinephrine pays off.
Industry Read-Through
Aquestive’s pivot highlights a broader trend among specialty pharma companies: as legacy revenue streams erode, survival increasingly depends on pipeline execution and launch excellence. The oral epinephrine category is poised for disruption, with DTC campaigns and expanded disease awareness growing the market but also raising the bar for differentiation. Competitors with device-free rescue therapies and strong commercial teams may see similar opportunities, but must also navigate payer access and regulatory hurdles. For the sector, the lesson is clear: capital efficiency, focused launch strategy, and adaptability to regulatory and market shifts are now prerequisites for value creation.